Solara Active Pharma Sciences Ltd
Fundamental Score
Solara Active Pharma Sciences Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SOLARA across key market metrics for learning purposes.
Positive Indicators
0 factors identified
No significant strengths identified in current analysis.
Risk Factors
15 factors identified
Below-Average Return on Equity (0.05%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.01%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Premium Valuation Risk (P/E: 361.52x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-226.09%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-9.63%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Limited Growth History (-0.58% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (-65.82% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-65.77% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Weak Interest Coverage (1.06x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-178.22 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
High Share Pledging Risk (35.32%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns or margin calls.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Financial Statements
Comprehensive financial data for Solara Active Pharma Sciences Ltd
About SOLARA
Business Overview
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, the company exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
Company Details
Key Leadership
Corporate Events
SOLARA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Solara Active Pharma Sciences Ltd (SOLARA)?
As of 29 Jan 2026, 10:35 am IST, Solara Active Pharma Sciences Ltd (SOLARA) is currently trading at ₹506.50. The stock has a market capitalization of ₹2.32K (Cr).
Is SOLARA share price Overvalued or Undervalued?
SOLARA is currently trading at a P/E ratio of 361.52x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Solara Active Pharma Sciences Ltd share price?
Key factors influencing SOLARA's price include its quarterly earnings growth (Sales Growth: -9.63%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Solara Active Pharma Sciences Ltd a good stock for long-term investment?
Solara Active Pharma Sciences Ltd shows a 5-year Profit Growth of -65.77% and an ROE of 0.05%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.51 before investing.
How does Solara Active Pharma Sciences Ltd compare with its industry peers?
Solara Active Pharma Sciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare SOLARA's P/E of 361.52x and ROE of 0.05% against the industry averages to determine its competitive standing.
What is the P/E ratio of SOLARA and what does it mean?
SOLARA has a P/E ratio of 361.52x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹362 for every ₹1 of annual earnings.
How is SOLARA performing according to Bull Run's analysis?
SOLARA has a Bull Run fundamental score of N/A/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SOLARA belong to?
SOLARA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Solara Active Pharma Sciences Ltd.
What is Return on Equity (ROE) and why is it important for SOLARA?
SOLARA has an ROE of 0.05%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Solara Active Pharma Sciences Ltd generates profits from shareholders' equity.
How is SOLARA's debt-to-equity ratio and what does it indicate?
SOLARA has a debt-to-equity ratio of 0.51, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is SOLARA's dividend yield and is it a good dividend stock?
SOLARA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has SOLARA grown over the past 5 years?
SOLARA has achieved 5-year growth rates of: Sales Growth -0.58%, Profit Growth -65.77%, and EPS Growth -65.82%.
What is the promoter holding in SOLARA and why does it matter?
Promoters hold 42.01% of SOLARA shares, with 35.32% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SOLARA's market capitalization category?
SOLARA has a market capitalization of ₹2317 crores, placing it in the Small-cap category.
How volatile is SOLARA stock?
SOLARA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SOLARA?
SOLARA has a 52-week high of ₹N/A and low of ₹N/A.
What is SOLARA's operating profit margin trend?
SOLARA has a 5-year average Operating Profit Margin (OPM) of 10.32%, indicating the company's operational efficiency.
How is SOLARA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -9.63% and YoY Profit Growth of -226.09%.
What is the institutional holding pattern in SOLARA?
SOLARA has FII holding of 13.58% and DII holding of 2.69%. Significant institutional holding often suggests professional confidence in the stock.